Atrium Therapeutics Prices $50M PIPE at $7.93/Share, Extends Runway Through 2028
RNA is trading near its 52-week low of $7.63 (3.9% above the low) on light trading volume (0.4× avg).
Summary
Atrium Therapeutics priced a $50 million PIPE at $7.93 per share with pre-funded warrants, extending its cash runway through 2028. The deal adds approximately 6.3 million shares, diluting existing holders by roughly 28%.
Key Events · Financing and Capital Events · RNA
-
$50M PIPE Priced At-The-Market
Atrium agreed to sell 5,170,384 shares at $7.93 per share and pre-funded warrants for 1,134,930 shares at $7.929 per warrant, for aggregate gross proceeds of approximately $50 million before placement agent fees.
-
Dilution of Approximately 28%
Post-offering share count will be 22,276,027 shares, up from approximately 15,970,713 shares before the offering — an increase of roughly 6.3 million shares, or about 28% dilution to existing holders.
-
Runway Extended Through 2028
Net proceeds combined with existing cash, cash equivalents, and investments are expected to fund operations through 2028, extending the runway beyond the 12+ months previously disclosed as of Q2 2026.
-
Institutional Investor Participation
The PIPE includes Sirenia Capital Management LP, Aberdeen Investments, Montanova, Sessa Capital, Casdin Capital, and a life sciences-focused institutional investor, with Leerink Partners as lead placement agent.
Analysis · RNA · Life Sciences
Atrium Therapeutics finalized a $50 million private placement priced at-the-market at $7.93 per share, selling 5,170,384 shares plus pre-funded warrants for 1,134,930 additional shares. The deal adds roughly 28% to the current share count and extends the company's cash runway through 2028 — a meaningful survival signal for a clinical-stage biotech trading near its 52-week low. The participation of established life-sciences investors including Casdin Capital and Sessa Capital provides some validation, but existing shareholders absorb the dilution at a price just above the 52-week low of $7.63.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.3% of the 1529 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNA was trading at $7.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $135.6M. The 52-week trading range was $7.63 to $16.77. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.